Colon cancer breakthrough keeps patients cancer-free for nearly 3 years

A UK-led trial has shown promising results for colorectal cancer treatment using pembrolizumab immunotherapy before surgery, keeping patients cancer-free for nearly three years. This approach challenges the standard method of surgery followed by months of chemotherapy. Patients received just nine weeks of pembrolizumab prior to surgery.